Search explainers, questions, and medicine profiles.
Research, perspective, and useful questions on this topic.
A 52-week mechanistic trial adds possible explanations for kidney protection, with null primary imaging results and small tissue subgroups.
The September 2026 trial adds evidence in type 2 diabetes, with two distinct weight-loss analyses and US approval still absent.
Read the dated Wegovy HD FDA approval, STEP UP dose-specific results and tolerability limits, without turning trial quantities into a dosing plan.
See why SYNCHRONIZE-2 reports 9.8% and 13.1% weight-loss estimates, what each analysis means, and the limits of the October 2026 news.
Read the September 2026 TRIUMPH-1 retatrutide results, their population and analysis limits, and the confirmed US investigational status.
Oral Wegovy in the EU progressed from a May recommendation to a July 2026 Commission decision. Read the current adult label and access limits.
What FDA’s January 2026 GLP-1 warning change means, how the evidence developed, and how to check the right regulatory document.
Foundayo received FDA approval on 1 April 2026. Read the confirmed adult indication, oral-use differences, safety context and remaining questions.
CagriSema has a documented US submission and new investigational results. Read the dated status, REDEFINE 1 evidence and what would confirm approval.
